Early-phase 18F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer’s disease: a comparison with 18F-FDG-PET and early-phase amyloid-PET

IF 8.6 1区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2025-01-24 DOI:10.1007/s00259-024-07063-4

Cecilia Boccalini, Debora Elisa Peretti, Gregory Mathoux, Leonardo Iaccarino, Federica Ribaldi, Max Scheffler, Daniela Perani, Giovanni B. Frisoni, Valentina Garibotto

{"title":"Early-phase 18F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer’s disease: a comparison with 18F-FDG-PET and early-phase amyloid-PET","authors":"Cecilia Boccalini, Debora Elisa Peretti, Gregory Mathoux, Leonardo Iaccarino, Federica Ribaldi, Max Scheffler, Daniela Perani, Giovanni B. Frisoni, Valentina Garibotto","doi":"10.1007/s00259-024-07063-4","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>As dual-phase amyloid-PET can evaluate amyloid (A) and neurodegeneration (N) with a single tracer injection, dual-phase tau-PET might be able to provide both tau (T) and N. Our study aims to assess the association of early-phase tau-PET scans and <sup>18</sup>F-fluorodeoxyglucose (FDG) PET and their comparability in discriminating Alzheimer’s disease (AD) patients and differentiating neurodegenerative patterns.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>58 subjects evaluated at the Geneva Memory Center underwent dual-phase <sup>18</sup>F-Flortaucipir-PET with early-phase acquisition (eTAU) and <sup>18</sup>F-FDG-PET within 1 year. A subsample of 36 participants also underwent dual-phase amyloid-PET (eAMY). Standardized uptake value ratios (SUVRs) were calculated to assess the correlation of eTAU and their respective <sup>18</sup>F-FDG-PET and eAMY scans. Hypometabolism and hypoperfusion maps and their spatial overlap were also evaluated at the individual level visually and semiquantitatively. Receiver operating characteristic analyses were performed to compare the discriminative power of eTAU, FDG, and eAMY SUVR between A-/T- and A+/T + participants.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Strong positive correlations were found between eTAU and FDG SUVRs (<i>r</i> = 0.84, <i>p</i> < 0.001) and eTAU and eAMY SUVRs (<i>r</i> > 0.87, <i>p</i> < 0.001). Clusters of significant hypoperfusion with good correspondence to hypometabolism topographies were found at the individual level, independently of the underlying neurodegenerative patterns. Both eTAU and FDG SUVRs significantly distinguished A+/T + from A-/T- individuals (AUC<sub>eTAU</sub>=0.604, AUC<sub>FDG</sub>=0.748) with FDG performing better than eTAU (<i>p</i> = 0.04). eAMY and eTAU SUVR showed comparable discriminative power.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Early-phase <sup>18</sup>F-Flortaucipir-PET can provide perfusion information closely related to brain regional glucose metabolism and perfusion measured by early-phase amyloid-PET, even if less accurate than FDG-PET as a biomarker for neurodegeneration.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"120 1","pages":""},"PeriodicalIF":8.6000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-024-07063-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

As dual-phase amyloid-PET can evaluate amyloid (A) and neurodegeneration (N) with a single tracer injection, dual-phase tau-PET might be able to provide both tau (T) and N. Our study aims to assess the association of early-phase tau-PET scans and ¹⁸F-fluorodeoxyglucose (FDG) PET and their comparability in discriminating Alzheimer’s disease (AD) patients and differentiating neurodegenerative patterns.

Methods

58 subjects evaluated at the Geneva Memory Center underwent dual-phase ¹⁸F-Flortaucipir-PET with early-phase acquisition (eTAU) and ¹⁸F-FDG-PET within 1 year. A subsample of 36 participants also underwent dual-phase amyloid-PET (eAMY). Standardized uptake value ratios (SUVRs) were calculated to assess the correlation of eTAU and their respective ¹⁸F-FDG-PET and eAMY scans. Hypometabolism and hypoperfusion maps and their spatial overlap were also evaluated at the individual level visually and semiquantitatively. Receiver operating characteristic analyses were performed to compare the discriminative power of eTAU, FDG, and eAMY SUVR between A-/T- and A+/T + participants.

Results

Strong positive correlations were found between eTAU and FDG SUVRs (r = 0.84, p < 0.001) and eTAU and eAMY SUVRs (r > 0.87, p < 0.001). Clusters of significant hypoperfusion with good correspondence to hypometabolism topographies were found at the individual level, independently of the underlying neurodegenerative patterns. Both eTAU and FDG SUVRs significantly distinguished A+/T + from A-/T- individuals (AUC_eTAU=0.604, AUC_FDG=0.748) with FDG performing better than eTAU (p = 0.04). eAMY and eTAU SUVR showed comparable discriminative power.

Conclusion

Early-phase ¹⁸F-Flortaucipir-PET can provide perfusion information closely related to brain regional glucose metabolism and perfusion measured by early-phase amyloid-PET, even if less accurate than FDG-PET as a biomarker for neurodegeneration.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

European Journal of Nuclear Medicine and Molecular Imaging 医学-核医学

CiteScore

15.60

自引率

9.90%

发文量

392

审稿时长

3 months

期刊介绍： The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.